Single agent- and combination treatment with two targeted suicide gene therapy systems is effective in chemoresistant small cell lung cancer cells

Journal of Gene Medicine

Volumn 14, Issue 7, 2012, Pages 445-458

  Michaelsen, Signe R ^a   Christensen, Camilla L ^a   Sehested, Maxwell ^b   Cramer, Frederik ^a   Poulsen, Thomas T ^a   Patterson, Adam V ^c   Poulsen, Hans S ^a  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Combination therapy; Resistance; Small cell lung cancer; Suicide gene therapy

Indexed keywords

3,5 DINITROBENZAMIDE 2 BROMOMUSTARD; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYTOSINE DEAMINASE; ETOPOSIDE; FLUCYTOSINE; FLUOROURACIL; INSULINOMA ASSOCIATED 1 PROTEIN; NITROREDUCTASE; SN 27686; TUMOR PROTEIN; UNCLASSIFIED DRUG; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IC 50; LUNG SMALL CELL CANCER; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SUICIDE GENE; SUICIDE GENE THERAPY;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; CYTOSINE DEAMINASE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; FLUCYTOSINE; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HUMANS; LUNG NEOPLASMS; MALE; MICE; NITROREDUCTASES; PENTOSYLTRANSFERASES; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; SMALL CELL LUNG CARCINOMA; YEASTS;

ESCHERICHIA COLI;

EID: 84864320391     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2630     Document Type: Article

References (60)

1. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001; 61(Suppl 1): 3-13.
2. Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc 2008; 83: 355-367.
3. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539-4544.
4. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008; 65: 3145-3167.
5. Kreisholt J, Sorensen M, Jensen PB, Nielsen BS, Andersen CB, Sehested M. Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer 1998; 77: 1469-1473.
6. Triller N, Korosec P, Kern I, Kosnik M, Debeljak A. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 2006; 54: 235-240.
7. Evans CD, Mirski SE, Danks MK, Cole SP. Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line. Cancer Chemother Pharmacol 1994; 34: 242-248.
8. Minato K, Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y, Saijo N. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol 1990; 26: 313-317.
9. Stewart DJ. Tumour and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 2010; 75: 173-234.
10. Kumar BS, Huang J, Persaud S, Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther 2004; 3: 327-334.
11. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 2002; 97: 584-592.
12. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002; 1: 913-922.
13. Poulsen TT, Pedersen N, Poulsen HS. Replacement and suicide gene therapy for targeted treatment of lung cancer. Clin Lung Cancer 2005; 6: 227-236.
14. Christensen CL, Zandi R, Gjetting T, Cramer F, Poulsen HS. Specifically targeted gene therapy for small-cell lung cancer. Expert Rev Anticancer Ther 2009; 9: 437-452.
15. Li Q, Notkins AL, Lan MS. Molecular characterization of the promoter region of a neuroendocrine tumour marker, IA-1. Biochem Biophys Res Commun 1997; 236: 776-781.
16. Pedersen N, Pedersen MW, Lan MS, Breslin MB, Poulsen HS. The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer. Cancer Gene Ther 2006; 13: 375-384.
17. Graepler F, Lemken ML, Wybranietz WA, et al. Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model. World J Gastroenterol 2005; 11: 6910-6919.
18. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822.
19. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338.
20. Christensen CL, Gjetting T, Poulsen TT, Cramer F, Roth JA, Poulsen HS. Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumour growth delay. Clin Cancer Res 2010; 16: 2308-2319.
21. Zenno S, Koike H, Tanokura M, Saigo K. Gene cloning, purification, and characterization of NfsB, a minor oxygen-insensitive nitroreductase from Escherichia coli, similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri. J Biochem 1996; 120: 736-744.
22. Singleton DC, Li D, Bai SY, et al. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). Cancer Gene Ther 2007; 14: 953-967.
23. Van Dillen IJ, Mulder NH, Sluiter WJ, et al. Consequences of chemoresistance for the herpes simplex virus thymidine kinase/ganciclovir-induced bystander effect in a human small cell lung cancer cell line model. Anticancer Res 2005; 25: 255-261.
24. Richard C, Duivenvoorden W, Bourbeau D, et al. Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy. Cancer Gene Ther 2007; 14: 57-65.
25. Wang Z, Cai L, Wang H. Gene therapy of adenovirus mediated CD: upp/5-FC directed by GSTP1 promoter in cisplatin-resistant ovarian cancer. Gynecol Oncol 2005; 96: 643-650.
26. Berendsen HH, de Leij L, de Vries EG, et al. Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res 1988; 48: 6891-6899.
27. Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985; 45: 2913-2923.
28. Jensen PB, Roed H, Sehested M, et al. Doxorubicin sensitivity pattern in a panel of small-cell lung-cancer cell lines: correlation to etoposide and vincristine sensitivity and inverse correlation to carmustine sensitivity. Cancer Chemother Pharmacol 1992; 31: 46-52.
29. Twentyman PR, Wright KA, Rhodes T. Radiation response of human lung cancer cells with inherent and acquired resistance to cisplatin. Int J Radiat Oncol Biol Phys 1991; 20: 217-220.
30. Jensen PB, Vindelov L, Roed H, et al. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Br J Cancer 1989; 60: 838-844.
31. Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 1997; 75: 869-877.
32. Poulsen TT, Naizhen X, Poulsen HS, Linnoila RI. Acute damage by naphthalene triggers expression of the neuroendocrine marker PGP9.5 in airway epithelial cells. Toxicol Lett 2008; 181: 67-74.
33. Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 1992; 52: 5674-5680.
34. Jensen PB, Christensen IJ, Sehested M, Hansen HH, Vindelov L. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br J Cancer 1993; 67: 311-320.
35. Jain N, Lam YM, Pym J, Campling BG. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer 1996; 77: 1797-1808.
36. Brock I, Hipfner DR, Nielsen BS, et al. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 1995; 55: 459-462.
37. Campling BG, Young LC, Baer KA, et al. Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 1997; 3: 115-122.
38. Carnero A. The PKB/AKT pathway in cancer. Curr Pharm Des 2010; 16: 34-44.
39. Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008; 27: 5527-5541.
40. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 1996; 32A: 912-920.
41. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 2010; 596: 47-76.
42. Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 2005; 5: 363-372.
43. Arnon J, Meirow D, Lewis-Roness H, Ornoy A. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update 2001; 7: 394-403.
44. Watson MB, Lind MJ, Cawkwell L. Establishment of in-vitro models of chemotherapy resistance. Anticancer Drugs 2007; 18: 749-754.
45. Davey RA, Locke VL, Henness S, Harvie RM, Davey MW. Cellular models of drug- and radiation-resistant small cell lung cancer. Anticancer Res 2004; 24: 465-471.
46. Wang YL, Yan YL, Zhou NJ, et al. Mechanism of multidrug resistance of human small cell lung cancer cell line H446/VP. Chin Med J (Engl) 2010; 123: 3299-3303.
47. Kim D, Dan HC, Park S, et al. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 2005; 10: 975-987.
48. Kraus AC, Ferber I, Bachmann SO, et al. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002; 21: 8683-8695.
49. Lan MS, Breslin MB. Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation. FASEB J 2009; 23: 2024-2033.
50. Duggan A, Madathany T, de Castro SC, Gerrelli D, Guddati K, Garcia-Anoveros J. Transient expression of the conserved zinc finger gene INSM1 in progenitors and nascent neurons throughout embryonic and adult neurogenesis. J Comp Neurol 2008; 507: 1497-1520.
51. Pedersen N, Mortensen S, Sorensen SB, et al. Transcriptional gene expression profiling of small cell lung cancer cells. Cancer Res 2003; 63: 1943-1953.
52. Ball DW, Azzoli CG, Baylin SB, et al. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumours. Proc Natl Acad Sci USA 1993; 90: 5648-5652.
53. Jiang T, Collins BJ, Jin N, et al. Achaete-scute complex homologue 1 regulates tumour-initiating capacity in human small cell lung cancer. Cancer Res 2009; 69: 845-854.
54. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22: 5323-5335.
55. Findeis-Hosey JJ, Huang J, Li F, Yang Q, McMahon LA, Xu H. High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not. Hum Pathol 2011; 42: 867-872.
56. Hill BT, Bellamy AS. Establishment of an etoposide-resistant human epithelial tumour cell line in vitro: characterization of patterns of cross-resistance and drug sensitivities. Int J Cancer 1984; 33: 599-608.
57. Shieh GS, Shiau AL, Yo YT, et al. Low-dose etoposide enhances telomerase-dependent adenovirus-mediated cytosine deaminase gene therapy through augmentation of adenoviral infection and transgene expression in a syngeneic bladder tumour model. Cancer Res 2006; 66: 9957-9966.
58. Boucher PD, Im MM, Freytag SO, Shewach DS. A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res 2006; 66: 3230-3237.
59. Aghi M, Kramm CM, Chou TC, Breakefield XO, Chiocca EA. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. J Natl Cancer Inst 1998; 90: 370-380.
60. Esaki T, Nakano S, Tatsumoto T, et al. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Cancer Res 1992; 52: 6501-6506.